1.62 USD
-0.12 (-6.9%)
1.63 USD
+0.01 (+0.62%)
We assign a fundamental rating of 2 out of 10 to CMMB. CMMB was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CMMB as it has an excellent financial health rating, but there are worries on the profitability. CMMB does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- In the past year CMMB has reported negative net income.
- In the past year CMMB has reported a negative cash flow from operations.
- CMMB had negative earnings in each of the past 5 years.
- In the past 5 years CMMB always reported negative operating cash flow.
1.2 Ratios
- CMMB has a worse Return On Assets (-106.24%) than 76.38% of its industry peers.
- CMMB has a Return On Equity (-121.90%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -106.24% | ||
| ROE | -121.9% | ||
| ROIC | N/A |
ROA(3y)-85.25%
ROA(5y)-73.64%
ROE(3y)-107.28%
ROE(5y)-89.93%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CMMB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, CMMB has more shares outstanding
- CMMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -2.59, we must say that CMMB is in the distress zone and has some risk of bankruptcy.
- CMMB has a Altman-Z score (-2.59) which is in line with its industry peers.
- CMMB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.59 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 7.42 indicates that CMMB has no problem at all paying its short term obligations.
- The Current ratio of CMMB (7.42) is better than 72.57% of its industry peers.
- CMMB has a Quick Ratio of 7.42. This indicates that CMMB is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of CMMB (7.42) is better than 72.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.42 | ||
| Quick Ratio | 7.42 |
3. Growth
3.1 Past
- CMMB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.42%, which is quite impressive.
EPS 1Y (TTM)61.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to grow by 14.01% on average over the next years. This is quite good.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.09%
EPS Next 2Y39.32%
EPS Next 3Y24.42%
EPS Next 5Y14.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for CMMB. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMMB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as CMMB's earnings are expected to grow with 24.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.32%
EPS Next 3Y24.42%
5. Dividend
5.1 Amount
- No dividends for CMMB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CHEMOMAB THERAPEUTICS LTD / CMMB FAQ
Can you provide the ChartMill fundamental rating for CHEMOMAB THERAPEUTICS LTD?
ChartMill assigns a fundamental rating of 2 / 10 to CMMB.
What is the valuation status for CMMB stock?
ChartMill assigns a valuation rating of 1 / 10 to CHEMOMAB THERAPEUTICS LTD (CMMB). This can be considered as Overvalued.
What is the profitability of CMMB stock?
CHEMOMAB THERAPEUTICS LTD (CMMB) has a profitability rating of 0 / 10.
What is the earnings growth outlook for CHEMOMAB THERAPEUTICS LTD?
The Earnings per Share (EPS) of CHEMOMAB THERAPEUTICS LTD (CMMB) is expected to grow by 94.09% in the next year.